Can this Positive Phase III Immunotherapy End Spinal Fractures due to Osteoporosis?

22/02/2016 - 3 minutes

UCB (Belgium) has a monoclonal antibody candidate (romozumab) which has met its primary endpoints for a phase III Osteoporosis trial, FRAME in partnership with Amgen. The drug showed 75% improvement (compared to placebo) and few side effects.

denosumab_osteoprorsis_ucb_amgen_vertebral_fractureUCB  in Brussels is developing immunotherapies for a range of chronic diseases, which has now gotten good phase III results for an Osteoporosis drug. This is developed in partnership with Amgen (US), which already has the first ever FDA approved antibody drug for osteoporosis (denosumab).

Osteoporosis is a common disease, with higher incidence in post-menopausal women. Characterised by low bone mineral density (BMD), there is an increased the risk of skeletal fractures – which can be really serious.

Romozumab is a monoclonal antibody that blocks sclerostin (a protein that inhibits bone formation), falling under the receptor activator of nuclear factor-κB ligand (RANKL) category of inhibitors.

Its effect in increasing BMD was evaluated in a previous phase II trial,

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
Do you want to remove this advert? Become a member!
Do you want to remove this advert? Become a member!

Support Us

Become a Member